These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10212925)

  • 1. Diffuse alveolar damage in BCGosis: a rare complication of intravesical bacillus Calmette-Guérin therapy for transitional cell carcinoma.
    Tan L; Testa G; Yung T
    Pathology; 1999 Feb; 31(1):55-6. PubMed ID: 10212925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent acid-fast bacilli following intravesical bacillus Calmette-Guerin.
    Linn R; Klimberg IW; Wajsman Z
    J Urol; 1989 May; 141(5):1197-8. PubMed ID: 2709508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary granulomata. A complication of intravesical administration of bacillus Calmette-Guerin for superficial bladder carcinoma.
    Smith RL; Alexander RF; Aranda CP
    Cancer; 1993 Mar; 71(5):1846-7. PubMed ID: 8448747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy.
    Aust TR; Massey JA
    Int J Urol; 2005 Oct; 12(10):920-1. PubMed ID: 16323989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy for bladder carcinoma.
    Marans HY; Bekirov HM
    J Urol; 1987 Jan; 137(1):111-2. PubMed ID: 3795348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin.
    Deresiewicz RL; Stone RM; Aster JC
    J Urol; 1990 Dec; 144(6):1331-3; discussion 1333-4. PubMed ID: 2231918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dystrophic bladder wall calcifications following intravesical BCG treatment for superficial transitional cell carcinoma of bladder.
    Spirnak JP; Lubke WL; Thompson IM; Lopez M
    Urology; 1993 Jul; 42(1):89-92. PubMed ID: 8328131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactive arthritis following BCG immunotherapy for bladder carcinoma.
    Tinazzi E; Ficarra V; Simeoni S; Peterlana D; Lunardi C
    Clin Rheumatol; 2005 Aug; 24(4):425-7. PubMed ID: 15660288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reiter syndrome after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy: a case report].
    Shiba M; Fujii T; Takatera H
    Hinyokika Kiyo; 2003 Oct; 49(10):599-601. PubMed ID: 14655604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder and penile lesions with inguinal adenopathy after intravesical Bacillus Calmette-Guerin (BCG) treatment.
    Yates J; Stein B
    Urology; 2007 Dec; 70(6):1223.e15-7. PubMed ID: 18158061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic bacillus-Calmette Guerin infection after transurethral administration for superficial bladder carcinoma.
    Sakamoto GD; Burden J; Fisher D
    J Urol; 1989 Oct; 142(4):1073-4; discussion 1074-5. PubMed ID: 2795734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
    Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
    J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
    [No Abstract]   [Full Text] [Related]  

  • 14. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer.
    Rawls WH; Lamm DL; Lowe BA; Crawford ED; Sarosdy MF; Montie JE; Grossman HB; Scardino PT
    J Urol; 1990 Dec; 144(6):1328-30. PubMed ID: 2231917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculous epididymitis following intravesical Bacillus Calmette-Guérin immunotherapy.
    Hoag N; Pommerville PJ; Kibsey PC; Cavers DJ; Eddy RJ
    Can J Urol; 2009 Apr; 16(2):4589-91. PubMed ID: 19364433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
    Rintala E; Jauhiainen K; Alfthan O; Hansson E; Juusela H; Kanerva K; Korhonen H; Permi J; Sotarauta M; Vaalasti T
    Eur Urol; 1991; 20(1):19-25. PubMed ID: 1743226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment.
    Paterson DL; Patel A
    Aust N Z J Surg; 1998 May; 68(5):340-4. PubMed ID: 9631906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulomatous chest disease following intravesical bacillus Calmette-Guerin immunotherapy.
    Chang H; Klein JS; Norotsky M; Cooper K
    J Thorac Imaging; 2004 Jan; 19(1):60-2. PubMed ID: 14712136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Miliary dissemination with pulmonary involvement secondary to intravesical immunotherapy with Calmette-Guérin bacillus].
    Paredes Arranz C; de Frutos Arribas JF; Calleja Escudero J; Blanco Cabero M; del Campo Matías F; Velasco MC
    Arch Bronconeumol; 1996 Feb; 32(2):100-2. PubMed ID: 8948873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multiorgan failure following intravesical bacillus Calmette-Guerin administration: a case report].
    Baba Y; Ishizu K; Jojima K; Joko K; Nakamura K; Takihara H; Naito K
    Hinyokika Kiyo; 1992 Sep; 38(9):1063-5. PubMed ID: 1414761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.